1. Introduction

Research funding compliance in Moroccan biotechnology programs refers to the legal, financial, administrative, ethical and institutional rules governing the receipt, allocation, expenditure, monitoring and auditing of funds used for biotechnology research.

Biotechnology research in Morocco covers several important areas, including:

Genetic engineering and genome-editing technologies.

Pharmaceutical and vaccine development.

Stem-cell and regenerative medicine research.

Agricultural biotechnology and genetically modified organisms (GMOs).

Genomic sequencing and personalized medicine.

Synthetic biology and industrial biotechnology.

Clinical trials and biomedical innovation.

Research funding may originate from the Moroccan government, public universities, international development institutions, private pharmaceutical companies, foreign research institutions and international scientific collaborations.

The principal legal challenge is ensuring that research funds are used for their authorized purposes while protecting scientific independence, public finances, research participants, intellectual property and biological materials.

Moroccan law does not establish one comprehensive statute exclusively governing biotechnology research funding. Instead, compliance results from the interaction of public-finance legislation, procurement rules, research and higher-education regulations, pharmaceutical legislation, personal-data protection and international agreements.

2. Legal Framework Governing Biotechnology Research Funding

A. Constitution of Morocco, 2011

The Moroccan Constitution provides the overarching legal foundation for public expenditure, scientific development, accountability and administrative transparency.

Relevant constitutional principles include:

Article 31: Establishes the State's responsibility to mobilize available resources to facilitate access to education, healthcare and other essential services.

Article 35: Recognizes the protection of property and the role of the State in promoting economic and social development.

Article 36: Addresses conflicts of interest, financial misconduct, corruption and the misuse of public resources.

Article 154: Establishes principles of transparency, accountability, quality and public-service performance.

Article 156: Requires public services to provide information and account for their management.

These constitutional principles are relevant when biotechnology research receives public grants, university funding or government-supported innovation financing.

For example, a public university receiving government funding for genetic research must demonstrate that the money has been allocated to the approved scientific project rather than diverted to unrelated institutional expenses.

B. Organic Law No. 130-13 on the Finance Law

Organic Law No. 130-13 establishes the framework for preparing, adopting and implementing Morocco's state budget.

Its relevance to biotechnology research includes:

Allocation of government research appropriations.

Classification of public expenditure.

Financial authorization and budget execution.

Monitoring of expenditure.

Performance-based public budgeting.

Accountability for the use of public funds.

A biotechnology research institution receiving public appropriations must ensure that expenditure corresponds to the authorized budgetary purpose.

For instance, funds allocated for vaccine-development laboratories cannot automatically be transferred to unrelated commercial activities without the required financial authorization.

C. Law No. 69-00 on State Financial Control

Law No. 69-00 governs state financial control over public establishments and other entities receiving public financial support.

It is particularly important for biotechnology research institutions that receive public subsidies.

Financial controls may concern:

Compliance with approved budgets.

Proper accounting procedures.

Verification of expenditure.

Internal financial controls.

Monitoring of public contributions.

Prevention of unauthorized spending.

Public biotechnology laboratories must maintain adequate financial documentation demonstrating the relationship between research expenditure and approved funding objectives.

D. Law No. 62-99 Establishing the Code of Financial Jurisdictions

Law No. 62-99 provides the framework for Morocco's financial courts, including the Court of Accounts.

The Court of Accounts supervises public financial management and examines whether public resources have been properly administered.

Its functions include examining financial accounts, assessing management irregularities and identifying circumstances involving financial responsibility.

This framework is relevant where public biotechnology funding is misused, inadequately documented or spent contrary to applicable financial requirements.

E. Law No. 59.24 on Higher Education and Scientific Research (2026)

An important recent development is Morocco's Law No. 59.24 on Higher Education and Scientific Research, promulgated in 2026.

This legislation is particularly relevant because it introduces a more developed institutional framework for financing and managing scientific research.

Important provisions include:

Article 102: Establishes a national information system to strengthen research and innovation governance and provide monitoring and evaluation indicators.

Article 103: Provides for the establishment of a national body responsible for mobilizing and managing financial resources allocated to scientific research and innovation, with legal personality and administrative and financial autonomy.

Article 104: Requires the State, territorial authorities, and public and private institutions to take measures to diversify and strengthen research-funding sources.

Article 105: Provides for partnership mechanisms through agreements to develop scientific research and innovation activities.

Article 106: Provides for measures to simplify expenditure procedures to facilitate the management of scientific research projects and improve implementation efficiency.

These provisions are significant for biotechnology because they provide a statutory foundation for diversifying research financing, institutional coordination and improved financial management.

For example, a Moroccan university conducting gene-therapy research may receive support through public appropriations, institutional research funds and research partnerships. The funding arrangements must still respect the applicable financial, contractual and ethical requirements.

The implementation of the national funding body and the practical operation of these provisions should be distinguished from their statutory establishment.

Eastlaws+1

3. Regulation of Public and Private Research Grants

Research funding in Moroccan biotechnology programs can be divided into several categories.

A. Government-funded biotechnology research

Government grants may support:

National genomic research programmes.

Vaccine development.

Agricultural biotechnology.

Disease surveillance.

Pharmaceutical innovation.

Public university laboratories.

The recipient institution must comply with the conditions of the grant, applicable budgetary rules and financial reporting requirements.

A grant agreement should specify:

The approved research objective.

The amount of funding.

The expenditure categories.

The project duration.

The reporting requirements.

The auditing arrangements.

The procedure for recovering misused funds.

B. University research funding

Public universities and research institutions must distinguish between institutional operating expenditure and project-specific funding.

For example, a university receiving funding for CRISPR gene-editing research should maintain separate records for:

Laboratory equipment.

Research chemicals.

Scientific personnel.

Sequencing services.

Laboratory maintenance.

External scientific consultancy.

Unapproved transfers between expenditure categories may create financial-compliance problems.

C. Private-sector biotechnology funding

Private companies may finance research through sponsorships, research contracts, licensing arrangements and collaborative development agreements.

These arrangements raise additional legal questions concerning:

Ownership of research results.

Patent rights.

Publication restrictions.

Confidentiality.

Conflicts of interest.

Commercial exploitation of discoveries.

A pharmaceutical company financing vaccine research at a public university should not automatically acquire ownership of every scientific discovery produced through that research. Ownership and exploitation rights should be determined by applicable intellectual-property legislation and the research agreement.

D. International research funding

Moroccan biotechnology institutions may participate in international research programmes and receive foreign funding.

International financing may involve:

Foreign universities.

International development agencies.

Multilateral research programmes.

Pharmaceutical companies.

International scientific foundations.

Such funding may require compliance with additional rules governing foreign-exchange transactions, international transfers, procurement, research ethics and reporting.

4. Research Funding Compliance and Public Procurement

Morocco's Decree No. 2-22-431 of 8 March 2023 on public procurement is important where biotechnology research institutions procure goods, services or works using funds covered by the decree.

Examples include:

Purchasing laboratory equipment.

Procuring genomic sequencing services.

Contracting pharmaceutical research laboratories.

Purchasing reagents and biological materials.

Constructing biosafety laboratories.

Hiring external scientific consultants.

The decree establishes procurement procedures and principles relevant to transparency, competition and the proper use of public resources.

Example:

A Moroccan public research institute receives government funding to establish a genomic sequencing laboratory. It purchases expensive sequencing machines from a supplier without following the procurement procedure applicable to the institution.

This could result in:

Procurement irregularities.

Financial audit objections.

Administrative consequences.

Contractual disputes.

Possible financial responsibility where the legal requirements are satisfied.

However, not every research grant is itself a public procurement contract. The legal classification depends on whether the transaction is a grant, subsidy, partnership agreement or purchase of goods and services.

tgr.gov.ma+2

5. Ethical Compliance in Biotechnology Research Funding

Funding compliance is not limited to financial expenditure. Biotechnology research must also satisfy ethical and scientific requirements.

A. Law No. 28-13 on the Protection of Persons Participating in Biomedical Research

Law No. 28-13 of 2015 establishes important safeguards for biomedical research involving human participants and their biological products.

Article 3 establishes principles including:

Respect for human life and health.

Protection of physical and psychological integrity.

Human dignity and privacy.

Voluntary participation.

Informed consent.

Good clinical research practices.

The non-commercial character of the human body.

Article 4 requires free, informed and express consent before biomedical research is conducted on a person, subject to the statutory exceptions.

Article 22 requires submission of the research project and protocol to the competent regional ethics committee for a reasoned opinion. Its assessment includes the appropriateness of the research, risks, benefits, investigator qualifications and compensation arrangements.

Article 26 establishes authorization requirements for interventional biomedical research.

Article 27 addresses the scientific and ethical conditions necessary for authorization, including the proportionality of foreseeable risks and expected benefits.

These provisions are particularly important when funding is provided for clinical trials, genetic screening, stem-cell research or experimental biological therapies.

Ma Loi+4

B. Financial incentives and research ethics

Research funding can create ethical conflicts when investigators receive personal financial benefits from sponsors.

For example, a pharmaceutical company may finance a clinical trial involving a new cancer treatment. If the investigator receives substantial additional compensation linked to positive trial results, this could compromise research independence.

Compliance therefore requires transparent financial arrangements, appropriate ethical review and accurate disclosure of investigators' interests.

C. Research involving genetic and personal data

Law No. 09-08 on the protection of individuals with regard to the processing of personal data is relevant to biotechnology programmes involving:

DNA sequencing.

Genetic databases.

Clinical records.

Patient information.

Genomic biobanks.

Health-related artificial intelligence.

Research funding agreements must not be treated as independent authorization to collect, process or transfer personal data.

The institution must separately satisfy the applicable data-protection requirements, including those concerning lawful processing, security and international transfers.

IRC+1

6. Institutional Supervision and Financial Accountability

Several institutions have important roles in supervising Moroccan biotechnology research funding.

A. Court of Accounts

The Court of Accounts is particularly important when public money is allocated to biotechnology programmes.

Its supervision can address:

Irregular expenditure.

Inadequate supporting documentation.

Failure to comply with financial procedures.

Mismanagement of public assets.

Improper use of institutional subsidies.

Financial responsibility of accountable officials.

B. Internal institutional audits

Research institutions should establish internal controls to verify whether expenditure corresponds to the approved research plan.

A biotechnology project should maintain:

A grant-receipt register.

A project-specific expenditure ledger.

Procurement documentation.

Employee and researcher payment records.

Equipment inventories.

Scientific progress reports.

Financial completion reports.

These documents help demonstrate that the funding has been used for its authorized purposes.

7. Case Laws and Judicial Principles

An important distinction must be made between directly applicable Moroccan judgments and comparative judicial authorities.

There is no sufficiently verified, publicly identifiable body of reported Moroccan judgments specifically concerning the misuse of biotechnology research grants. Consequently, it would be misleading to invent case names or suggest that general financial judgments directly decided biotechnology funding disputes.

Nevertheless, the following legal authorities provide important principles for interpreting research funding compliance.

A. Moroccan legal authorities and adjudicatory framework

1. Court of Accounts financial-management decisions

The Moroccan Court of Accounts exercises jurisdiction over public financial accountability under the financial-jurisdiction framework established by Law No. 62-99.

Its financial-control principles are relevant where public biotechnology funding has been misused, improperly accounted for or administered contrary to applicable financial requirements.

For example, if a public laboratory spends vaccine-development funding on unrelated commercial expenses, the responsible institution and officials may face financial scrutiny under the applicable rules.

This is a relevant institutional adjudicatory framework, rather than a citation to a specific biotechnology judgment.

2. Administrative procurement disputes

Moroccan administrative courts may become relevant when disputes concern public procurement decisions, administrative contracts, public authorities or the exercise of administrative powers.

For instance, a biotechnology institution may challenge a procurement decision or a supplier may dispute the legality of a public contract award.

Decree No. 2-22-431 provides the relevant procurement framework. However, a procurement dispute should not automatically be described as a research-grant judgment.

3. Biomedical research authorization disputes

Law No. 28-13 provides the legal framework for authorization and ethical supervision of biomedical research.

Where a funded project fails to obtain the required authorization, its financial sponsor cannot treat the existence of funding as permission to conduct the research.

The statutory provisions concerning ethics review and authorization therefore provide an important legal basis for determining whether a funded biomedical project can proceed.

Ma Loi+2

B. Comparative judicial precedents

The following judgments are useful for understanding legal principles that can arise in internationally funded biotechnology projects. They are comparative authorities, not binding Moroccan precedents.

1. S. and Marper v. United Kingdom (2008), European Court of Human Rights

This case concerned the retention of fingerprints and DNA profiles by public authorities.

The Court found that indefinite retention of the applicants' biometric data violated Article 8 of the European Convention on Human Rights.

Relevance to biotechnology funding: A publicly funded genomic database must not disregard privacy and data-protection requirements merely because its research objectives are scientifically beneficial.

2. Evans v. United Kingdom (2007), European Court of Human Rights

This case concerned the use and storage of embryos created through assisted reproductive technology.

The Court examined reproductive autonomy, consent and competing rights.

Relevance to biotechnology funding: Financial sponsorship of embryo research cannot override the legal and ethical requirements governing consent and reproductive materials.

3. Costa and Pavan v. Italy (2012), European Court of Human Rights

This case concerned access to preimplantation genetic diagnosis and the compatibility of restrictions with private and family life.

Relevance to biotechnology funding: Funding programmes supporting genetic screening and reproductive technologies must take account of human rights, access, discrimination and ethical safeguards.

4. V.C. v. Slovakia (2011), European Court of Human Rights

This judgment concerned sterilization without valid informed consent.

Relevance to biotechnology funding: Financial incentives, research protocols and institutional targets must never displace the requirement for meaningful consent in biomedical interventions.

IRC+1

These comparative judgments offer interpretive guidance on privacy, autonomy and informed consent. They do not establish Moroccan rules on the allocation or recovery of research grants.

8. Misuse of Research Funding and Legal Consequences

Funding violations may create civil, administrative, financial or criminal consequences depending on the facts and the applicable legal provisions.

Example 1: Misappropriation of genomic research funds

A public university receives MAD 5 million to establish a national genomic sequencing laboratory.

The project director uses MAD 1 million for unrelated commercial activities.

Potential legal issues include:

Breach of grant conditions.

Unauthorized expenditure.

Financial accountability.

Possible criminal investigation if the conduct satisfies the relevant criminal-law requirements.

Example 2: Falsification of biotechnology expenditure

A research institution submits fabricated invoices for expensive laboratory reagents.

This may lead to:

Financial audit investigations.

Rejection of unsupported expenditure.

Recovery of funds.

Disciplinary action.

Criminal proceedings where fraud or other offences are established.

Example 3: Foreign-funded clinical research

A foreign pharmaceutical company finances a Moroccan clinical trial involving an experimental vaccine.

The sponsor must ensure that the project complies with applicable requirements concerning:

Biomedical research authorization.

Ethics committee review.

Participant consent.

Financial transparency.

Data protection.

Management of experimental medicines.

Funding approval alone does not replace regulatory authorization.

The AMMPS published a guideline on the management and traceability of experimental medicines on 24 April 2026. It addresses importation, monitoring, reconciliation, destruction, documentation and record-keeping in clinical trials.

AMMPS+1

9. International Funding and Cross-Border Compliance

International biotechnology funding introduces additional regulatory obligations.

Moroccan research institutions participating in international programmes should examine the following issues.

A. International financial transfers

Foreign-funded research projects may involve international payments, foreign-currency transactions and transfers to overseas research partners.

Institutions should maintain appropriate records of:

Funding agreements.

International payments.

Foreign research contributions.

Currency conversions.

Payments to foreign laboratories.

Financial reporting obligations.

B. Intellectual property ownership

International biotechnology agreements should clearly establish ownership of inventions, research data, patents and commercially exploitable discoveries.

Morocco's Law No. 17-97 on the protection of industrial property, as amended, is relevant to patent rights.

For example, where a Moroccan university and a European pharmaceutical company jointly develop a vaccine, their agreement should specify patent ownership, licensing rights, commercial revenues and publication rights.

C. Biological materials and genetic information

International research funding may involve the movement of biological samples, human genetic information and laboratory materials across national borders.

Such activities require consideration of applicable Moroccan requirements governing:

Human biological materials.

Biomedical research authorization.

Personal-data protection.

Import and export controls.

Research-participant consent.

Applicable international agreements.

D. International research standards

Internationally financed research may also be subject to contractual requirements based on:

Good Clinical Practice (GCP).

Good Laboratory Practice (GLP).

World Health Organization research standards.

International research ethics principles.

Relevant donor financial-management standards.

These requirements become enforceable through Moroccan law where incorporated into applicable legal instruments, regulations or contractual obligations.

10. Major Legal Challenges in Morocco

Several challenges affect the implementation of research funding compliance in Moroccan biotechnology programmes.

1. Fragmented regulation: Financial, scientific, ethical and pharmaceutical requirements are distributed across different legal instruments.

2. Financial transparency: Some institutions may lack sufficiently developed project-level accounting and expenditure-monitoring systems.

3. Research independence: Private sponsors may seek contractual influence over publication, research outcomes and intellectual property.

4. International funding complexity: Foreign grants may impose reporting and procurement obligations that differ from domestic procedures.

5. Ethical supervision: Funding availability does not guarantee that a research project has received appropriate ethical and regulatory approval.

6. Institutional capacity: Advanced biotechnology programmes require specialized financial auditors who understand scientific expenditure, clinical research and laboratory procurement.

7. Implementation of Law No. 59.24: The new national funding architecture requires effective institutional implementation, coordination and supporting regulations.

11. Recommendations for Strengthening Legal Compliance

Morocco could strengthen biotechnology research funding governance through the following measures:

Establish standardized national biotechnology grant agreements.

Introduce project-specific digital financial reporting.

Require independent audits for substantial publicly funded research projects.

Strengthen conflict-of-interest disclosure requirements.

Establish clear rules for international research partnerships.

Link funding disbursement to verified scientific and financial milestones.

Improve coordination between research institutions, financial regulators and health authorities.

Strengthen protection of research participants and genomic information.

Establish transparent rules for intellectual property and commercialization.

Develop specialized training for biotechnology research financial administrators.

12. Conclusion

Regulation of research funding compliance in Moroccan biotechnology programmes is an important component of scientific governance, public financial accountability and responsible technological development.

The legal framework combines constitutional principles, public-finance legislation, procurement regulations, biomedical research legislation, personal-data protection and institutional oversight.

Law No. 59.24 of 2026 is a particularly important development. Its Articles 102–106 provide for national research information infrastructure, a dedicated research-funding body, diversified funding sources, partnership arrangements and simplified research expenditure procedures. Articles 107–108 additionally address monitoring, institutional evaluation and quality assurance.

Law No. 28-13 complements this framework by protecting research participants and establishing scientific and ethical conditions for biomedical research.

Ultimately, Moroccan biotechnology research funding must satisfy three interconnected requirements:

Financial legality: Money must be allocated and spent according to applicable legal and contractual requirements.

Scientific accountability: Funded activities must pursue legitimate research objectives and maintain appropriate scientific standards.

Ethical responsibility: Research must respect human dignity, informed consent, privacy and applicable safety requirements.

A transparent funding system can support Morocco's development of pharmaceutical innovation, genomic medicine, agricultural biotechnology and advanced biomedical research while strengthening public confidence in scientific institutions.

13. Important Legal References and Research Sources

Useful primary and institutional sources:

Morocco Law No. 59.24 – full legislative text.

Moroccan Ministry of Justice – Legal Portal.

Law No. 28-13 – Biomedical Research Protection.

Public Procurement Decree No. 2-22-431.

AMMPS – Experimental Medicines Traceability Guideline (2026).

National Commission for Public Procurement – Legal Documents.

Legal research qualification: The comparative European judgments above are not binding Moroccan precedents. A complete case-law treatment would require verification of specific Moroccan Court of Accounts decisions and administrative or criminal judgments against official judicial records. The statutory framework is more directly established than a biotechnology-specific body of reported case law.